Curis shares fall 13% after-hours as dilutive $80.8M private placement including $0.75 warrants sparks investor concerns.

Curis Inc. (NASDAQ: CRIS) fell 13.0% in after-hours trading following the announcement of an $80.8 million private placement, including $20.2 million in initial proceeds, to fund research and development of its drug candidate emavusertib. The financing involves issuing convertible preferred stock and warrants exercisable at $0.75 per share, with participation from executives and insiders. The move signals financial strain, as the company reported a $7.7 million net loss for Q3 2025 and faces a current ratio of 0.7. While the capital aims to advance clinical trials, the issuance of dilutive securities and reliance on insider funding likely raised concerns among investors, prompting the sharp decline.